PharmaEssentia

PharmaEssentia EBITDA per Employee

EBITDA per Employee of PharmaEssentia (6446.TW) as of Nov 19, 2026.

EBITDA per Employee

-TWD

Last updated:

EBITDA per Employee of PharmaEssentia is 2026 - TWD. EBITDA per Employee of PharmaEssentia was 2025 - TWD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEssentia Stock analysis

What does PharmaEssentia do? PharmaEssentia Corp develops and sells drugs for hematology, infectious diseases, dermatology, and neurology. Its products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, and PEG-EPO, targeting conditions like MPN, hepatitis C, psoriasis, and multiple sclerosis. The company sells these drugs domestically in Taipei and internationally to overseas markets. The firm generates revenue through the sale of its pharmaceutical products to healthcare providers and distributors. Its research and development focus on new drugs for specific medical conditions, with products distributed across multiple therapeutic areas. PharmaEssentia Corp's market segments include hematology, infectious disease, dermatology, and neurology, serving both local and global healthcare systems. PharmaEssentia Corp's business model centers on developing and commercializing prescription drugs for specialized medical treatments. The company's product portfolio targets high-demand therapeutic areas, with sales driven by both domestic and international distribution channels. Its revenue streams are derived from the ongoing sale of established products and the pipeline of new drug developments. PharmaEssentia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEssentia stock

On Eulerpool you can find the complete historical development of EBITDA per Employee PharmaEssentia since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's PharmaEssentia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — PharmaEssentia

All Key Metrics — PharmaEssentia